InvestorsHub Logo

mr_freemoney

08/05/21 1:45 PM

#110047 RE: uvaphd #110046

Yes, they've diverged some, however I was referring to the commonality of Dr. Thomas Ichim mostly, and if he's gaining approvals from the FDA on JadiCell, he's likely having discussions about ImmCelz and MyeloCelz as well. I would not be surprised to hear about approvals for these in the near future.

Though I agree that TSOI is much farther along and has an advantage at the moment.